It's no longer a question of will Baltimore Ravens wide receiver Breshad Perriman play this season. It's now a question of when he'll return to the field in 2016.
Arthroscopic surgery on Tuesday revealed that Perriman does not have a torn anterior cruciate ligament and will not need season-ending knee surgery, a source told ESPN's Adam Schefter. He is expected to be "fine" for the regular season, the source added.
But, for anyone who followed Perriman's drama-filled rookie season, there are simply no guarantees when it comes to timetables with the 2015 first-round pick.
It'll be interesting to see if the Ravens provide an estimated return date, given that his prolonged recovery last season was cloaked in mystery. If you remember, Perriman was told by doctors that he was only going to miss a couple of days when he hurt his right knee on the first day of training camp, but he eventually missed the entire season.
At one point in 2015, coach John Harbaugh lamented that Perriman had "probably one of the all-time slowest healing sprained PCLs ever." Ravens officials weren't even sure Perriman was fully running a month before offseason practices began.
The Ravens can only hope his left knee recovers much quicker. Perriman received a stem-cell injection in the joint Tuesday, and the injury will be allowed to heal on its own.
This is great news for the Ravens and Perriman, who can breathe a sigh of relief having avoided another lost season. Even though the Ravens were in better shape to deal with his absence with the additions of Mike Wallace and rookie Chris Moore, Perriman should be the team's best deep threat.
Perriman is seven years younger than Wallace, and he was drafted three rounds earlier than Moore. He has the size (6-foot-2, 218 pounds) and speed (4.2 seconds 40-yard time at his pro day) that teams covet at the wide receiver position.
Based on the reports, it looks like he'll only be sidelined for a couple of months. But recent history suggests that it could still be too early to tell.
































